CBR3 and cancer: In survivors treated for heterogeneous types of cancers, the CBR3-rs1056892-GG variant genotype showed an increased risk of developing cardiomyopathy (OR = 1.79, 95% CI: 1.08–2.96), p = 0.02) [25], and also showed an interaction effect with exposition to low-to-moderate doses of anthracycline (1–250 mg/m2), increasing by 3.3-fold increased risk of cardiomyopathy compared to GA and AA genotypes [25].